The effects of different treatments on prolidase and antioxidant enzyme activities in patients with bronchial asthma

Kaleli S., Akkaya A., Akdogan M., Gultekin F.

ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY, vol.22, no.1, pp.35-39, 2006 (SCI-Expanded) identifier identifier identifier


The effects of two different treatment combinations of bronchial asthma on antioxidant defense systems and serum prolidase activity were investigated. The groups were organized as follows: the first group (control) consisted of healthy subjects. The second group (treatment 1) consisted of patients with bronchial asthma inhaling budesonide (2 x 400 mcg/d, as puff) + formaterol (2 x 9 mcg/d, as puff). In the third group (treatment 2) patients with bronchial asthma were treated with montelukast (1 x 10 mg/d, as pill) + budesonide (2 x 400 mcg/d, as puff) + formaterol (2 x 9 mcg/d, as puff). The medical therapy of the patients in treatment I and treatment 2 lasted 12 weeks. Before and after treatment in all three groups blood samples were taken and the level of thiobarbituric acid-reactive substances (TBARS) and the activities of prolidase, superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), glutathione reductase (GSSG-Rd) and catalase (CAT) were measured. Prolidase activity was found to be significantly higher in patients compared to control (p < 0.05). Treatment 2 was successfully reduced the prolidase activity (p < 0.05). Before treatments, SOD activity was significantly decreased whereas TBARS level and other antioxidant enzymes were increased in both treatment groups comparing with control (p < 0.05). Both of different treatments given in treatment I and treatment 2 groups caused significant increase in SOD whereas decrease in TBARS, CAT, GSSG-Rd, GSH-Px (p < 0.05). When compared the treatment groups after treatments, SOD activity was significantly higher in treatment 2 group than treatment 1 group (p < 0.05). No significant difference was seen in other parameters. The balance between oxidant-antioxidant system is impaired in patients with asthma. (c) 2005 Elsevier B.V. All rights reserved.